Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CNS Pharmaceuticals Inc CNSP

Healthcare
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for... see more

Recent & Breaking News (NDAQ:CNSP)

WPD Pharmaceuticals and CNS Pharmaceuticals Announce Additional Coronavirus Testing on WP1122 by ImQuest Biosciences

GlobeNewswire April 21, 2020

CNS Pharmaceuticals Announces Shareholder Webinar to Discuss Collaboration with WPD Pharmaceuticals for Developing Coronavirus Drug Candidates, the Significance of WP1244, and an Update on the Cancer Free Survivor Treated with Berubicin

PR Newswire April 15, 2020

CNS Pharmaceuticals Announces Independent University Research Confirms Active Compound in WP1122 Completely Prevents Coronavirus Replication In Vitro; WP1122 is Subject to Development Agreement with WPD Pharmaceuticals

PR Newswire April 13, 2020

WPD Pharmaceuticals Reports Active Compound in Licensed Drug Candidate Reduces Coronavirus Replication in Vitro by 100%

GlobeNewswire April 9, 2020

WPD Pharmaceuticals Partners with CNS Pharmaceuticals on Drug Development for Coronavirus and Other Antiviral Indications

GlobeNewswire March 24, 2020

CNS Pharmaceuticals Announces Business Highlights and 2019 Fourth Quarter Financial Results

PR Newswire March 12, 2020

CNS Pharmaceuticals to Report Fourth Quarter 2019 Financial Results on March 12, 2020

PR Newswire March 5, 2020

WPD Pharmaceuticals' Brain Cancer Drug Received Positive FDA Pre-IND Guidance

GlobeNewswire March 4, 2020

CNS Pharmaceuticals Announces Brain Cancer Patient from Berubicin Phase 1 Trial Remains Cancer Free

PR Newswire March 3, 2020

CNS Pharmaceuticals to Ring Nasdaq Stock Market Opening Bell on March 3

PR Newswire February 27, 2020

CNS Pharmaceuticals Announces Collaboration with European Partner to Expand Clinical Trials to Pediatric Brain Tumors

PR Newswire February 11, 2020

CNS Pharmaceuticals Announces Completion of GMP Manufacturing

PR Newswire February 4, 2020

CNS Pharmaceuticals Completes Pilot Manufacturing Steps Pursuant to FDA Pre-IND Guidance

PR Newswire January 28, 2020

CNS Pharmaceuticals Announces Contract with International GMP Manufacturer for Production of Berubicin

PR Newswire January 14, 2020

CNS Pharmaceuticals Licenses Breakthrough Technology from MD Anderson, Doubling its Drug Pipeline

PR Newswire January 13, 2020

CNS Pharmaceuticals Partnered with Anthem Biosciences Pvt. Ltd. in Preparation for Upcoming Proposed Phase 2 Clinical Trial

PR Newswire December 17, 2019

CNS' Berubicin Awarded $5.8 Million Non-Dilutive Grant from EU/Polish National Center Through its Development Partner

PR Newswire December 11, 2019

CNS Pharmaceuticals Received Positive FDA Pre-IND Guidance for Berubicin

PR Newswire December 10, 2019

CNS Pharmaceuticals to Participate in 12th Annual LD Micro Main Event Conference

PR Newswire December 3, 2019

CNS Pharmaceuticals Entered $2.0 Million Sublicense Agreement with WPD Pharmaceuticals

PR Newswire November 26, 2019